Biokier, Inc.

Glaxo Wellcome Inc.

Smithkline Beecham Corporation

Trana Discovery, Inc.

Glaxosmithkline LLC

Jerzy Ryszard Szewczyk

Elizabeth Ellen Sugg

Richard H Guenther

Ronald George Sherrill

Christopher Joseph Aquino

Timothy Mark Willson

Jason Daniel Speake

Milana Dezube

Harry Finch

Stephen Andrew Thomson

David John Cowan

Andrew Lamont Larkin

Dulce Garrido Bubacz

Samuel Perry Yenne

Gavin Charles Hirst

Douglas McCord Sammond

Ed Williams McLean

Jennings Franklin Worley, Iii

Robin Arthur Carr

Kelly H Donaldson

Andrew James Peat

Kevin Karl Barvian

Robert Anderson Noe

Iain David Dukes

Methods of inhibitingpropagation, and screening for compounds that inhibitpropagation, are described. A method of inhibitingpropagation comprises either inhibiting or stabilizing ribosomal binding of a specifictRNA in theby an amount sufficient to inhibitprotein expression. A method of screening for compounds useful for inhibitingpropagation comprises contacting a specifictRNA to a ribosome that binds that tRNA in the presence of the test compound and an mRNA that codes for methionine and arginine (i.e., includes the sequence AUGAGA), and then determining whether the compound inhibits the binding of that tRNA.

[object Object]

Inhibitors of retroviral propagation, methods of treatment and prevention of retroviral infections using the inhibitors, and pharmaceutical compositions including the inhibitors, are disclosed.

Antiviral compounds and methods of use thereof

The present invention relates to a method of treating NASH or NAFLD by delivery of an effective amount of a composition comprising L-glutamine or butyric acid formulated for release in the colon by bypassing the upper digestive tract and stomach.

Composition and method for treatment of NASH

The present invention relates to a method of treating an incretin related disease such as diabetes, obesity and the like by delivery of butyric acid, bile acid, long chain fatty acid or glutamine to the colon by bypassing the upper digestive tract. The composition is combined either by the same or different route of administration with a monoamine reuptake inhibitor such as buproprion.

Composition and method for treatment of diabetes

The present invention is drawn to a pharmaceutical composition comprising the following compound:  The compound and other azacycle derivatives can be used in method of treatments for retroviral infections, such as HIV.

The present invention relates to a method of treating an incretin related disease such as diabetes, obesity and the like by delivery of long chain fatty acid to the colon by bypassing the upper digestive tract.

The present invention relates to a method of treating an incretin related disease such as diabetes, obesity and the like by delivery of butyric acid, bile acid, long chain fatty acid, or glutamine to the colon by bypassing the upper digestive tract.

The present invention relates to novel compounds which are antagonist or inverse agonists at an opioid receptor. Such compounds are useful in the treatment of obesity and related diseases and/or conditions in mammals, particularly humans. Methods of making and using such compounds are also disclosed.

Heterocycle compounds

There is provided novel diazepines that function as agonists at the melanocortin 4 receptor and as agonists at the melanocortin 1 receptor, pharmaceutical compositions containing them, methods for their use in treatment, and processes for their preparation.

Diazepine compounds as ligands of the melanocortin 1 and/or 4 receptors

The present invention provides a compound of formula I comprising: a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof.

Compounds

The invention relates to methods of treatment of non insulin dependent diabetes mellitus, antagonists of the delayed rectifier potassium channel Kv2.1, methods of using and preparing the antagonists and assays for identifying such antagonists.

Growing community of inventors

Chapel Hill, NC, United States of America

Jerzy Ryszard Szewczyk